114. 非ジストロフィー性ミオトニー症候群 ［臨床試験数：6，薬物数：5（DrugBank：4），標的遺伝子数：18，標的パスウェイ数：10］
Searched query = "Non dystrophic myotonia syndrome", "Non dystrophic Myotonia", "Myotonia congenita", "Paramyotonia congenita", "Thomsen disease", "Becker disease", "Sodium channel myotonia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02251457 | August 2014 | 18 March 2019 | Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1 | Open Label Trial of Ranolazine in Myotonia Congenita, Paramyotonia Congenita, & Myotonic Dystrophy Type 1 | Myotonia Congenita;Paramyotonia Congenita;Myotonic Dystrophy 1 | Drug: Ranolazine | Ohio State University | Gilead Sciences | Not recruiting | 18 Years | 100 Years | All | 35 | Phase 1 | United States |
| 2 | NCT01939561 | November 2013 | 2 May 2016 | Lamotrigine as Treatment of Myotonia | Lamotrigine as Treatment of Myotonia - a Phase 3 Randomized Controlled Trial Study | Dystrophia Myotonica Type 1;Myotonia Congenita;Paramyotonia Congenita;Hyperkalemic Periodic Paralysis;Potassium-Aggravated Myotonia | Drug: Lamotrigine;Drug: Placebo | Grete Andersen, MD | Not recruiting | 18 Years | N/A | Both | 27 | Phase 3 | Denmark | |
| 3 | EUCTR2010-024026-38-NL | 10/01/2012 | 19 March 2012 | Combining N-of-1 trials to estimate population clinical effectiveness of drugs using Bayesian hierarchical modeling. The case of Mexilitin for patients with Non-Dystrophic Myotonia. - Mex vs. placebo in NDMs | Combining N-of-1 trials to estimate population clinical effectiveness of drugs using Bayesian hierarchical modeling. The case of Mexilitin for patients with Non-Dystrophic Myotonia. - Mex vs. placebo in NDMs | Patients with non-dystrophic myotonic syndromes (NDMs). NDMs are caused by mutations in the gene encoding for the skeletal muscle sodium (SCN4A) or chloride (CLCN1) channel. In this study patients with NDMs with a genetically confirmed mutation in the SCN4A-gene or the CLCN1-gene as registred in the Netherlands database of NDMs will be included. | Trade Name: Mexitil Product Name: mexitil Pharmaceutical Form: Tablet INN or Proposed INN: MEXILETINE CAS Number: 31828714 Current Sponsor code: - Other descriptive name: Mexitil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 600 - Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Radboud University Nijmegen Medical Center | Authorised | Female: yes Male: yes | 30 | Netherlands | ||||
| 4 | NCT02336477 | June 2011 | 19 February 2015 | Mexiletine and Non Dystrophic Myotonias | Efficacy and Safety of Mexiletine in Non-dystrophic Myotonias | Non-dystrophic Myotonias;Paramyotonia Congenita;Myotonia Congenita | Drug: Mexiletine;Drug: placebo | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | 65 Years | Both | 24 | Phase 3 | France | |
| 5 | NCT00832000 | December 2008 | 19 October 2017 | Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia | Phase II Therapeutic Trial of Mexiletine in Non-Dystrophic Myotonia | Myotonia;Non-Dystrophic Myotonia | Drug: Mexiletine;Drug: Placebo | Richard Barohn, MD | Not recruiting | 16 Years | N/A | All | 59 | Phase 2 | United States;Canada;Italy;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00004802 | June 1992 | 19 February 2015 | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders | Paralysis, Hyperkalemic Periodic;Hypokalemic Periodic Paralysis;Paramyotonia Congenita | Drug: dichlorphenamide | National Center for Research Resources (NCRR) | Ohio State University | Not recruiting | 10 Years | 75 Years | Both | 64 | Phase 3 |